Clinical translation of METTL3 inhibition is underway (STC-15, phase I), and preclinical work supports combining writer or eraser inhibitors with standard therapies (e.g., venetoclax in AML; RT in HNSCC). This evidence concerns the gene METTL3 and head and neck squamous cell carcinoma.